tegafur has been researched along with Leukocytopenia in 96 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 9.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 9.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer." | 9.14 | Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 9.05 | [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1984) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | 7.67 | [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 7.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 6.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 6.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| "Combination chemotherapy consisting of carboplatin plus S-1 and concurrent TRT had a promising efficacy in elderly patients with locally advanced NSCLC; however, radiation pneumonitis was frequently observed." | 5.30 | Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study. ( Akimoto, T; Goto, K; Hida, T; Hosomi, Y; Nihei, K; Niho, S; Ohe, Y; Okamoto, H; Tanaka, H; Umemura, S, 2019) |
| "Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)." | 5.24 | A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 5.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "To evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer." | 5.14 | Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. ( Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I, 2010) |
| "Nab-paclitaxel plus S1 was more efficient in terms of ORR and DCR than S1 monotherapy in elderly pancreatic ductal adenocarcinoma patients while the side effect was controllable with a higher probability of leukopenia." | 5.12 | Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. ( Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M, 2021) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The combination of epirubicin, cisplatin and UFT showed anticancer activity against metastatic gastric adenocarcinoma, had a tolerable toxicity profile and showed excellent patient compliance." | 5.11 | A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. ( Byun, JH; Choi, MG; Chung, IS; Hong, YS; Kang, JH; Kim, KW; Lee, KS; Lee, MA; Moon, DH; Park, SY; Shim, BY; Woo, IS, 2005) |
| " Major toxicities were leukopenia (38%), anorexia (27%), increased total bilirubin concentration (25%) and diarrhea (24%)." | 5.10 | [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| "Thirty-nine patients with locally advanced or metastatic gastric carcinoma received oral UFT (tegafur and uracil) plus leucovorin." | 5.08 | A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma. ( Kim, BS; Kim, JG; Kim, JS; Kim, YH; Park, YT; Shin, SW, 1997) |
| "A prospective randomized trial was conducted to compare the clinical responses of sixty patients with advanced breast cancer to a combination of adriamycin, cyclophosphamide and oral ftorafur (ACF), or to a combination of ACF plus methotrexate (ACFM)." | 5.05 | [A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer]. ( Adachi, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Nakada, H; Ogawa, M; Tada, A; Usui, N; Yamazaki, H, 1984) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "A combination therapy of irinotecan hydrochloride (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is often used to treat advanced colorectal cancer." | 4.83 | [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule]. ( Goto, A, 2006) |
| "Concomitant treatment with 5-fluorouracil (5-FU) and Leucovorin (LV) is positioned as the standard chemotherapy against colorectal cancer." | 3.72 | [Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer]. ( Anazawa, S; Hirai, K; Kawahara, H; Ogawa, M; Sakuyama, T; Sato, K; Takao, Y; Yamazaki, Y; Yokoyama, M, 2004) |
| "Twenty-nine patients with metastatic breast cancer were treated with a combination chemotherapy consisting of Epirubicin 50 mg/m2 IV on day 1, Cyclophosphamide 500 mg/m2 IV on day 1 and Ftorafur 800 mg/day PO every day (ECF therapy)." | 3.67 | [Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer]. ( Fukutani, H; Hirano, A; Horikoshi, N; Inoue, K; Mizunuma, N; Mukaiyama, T; Ogawa, M; Shinagawa, K; Tabata, M, 1988) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 3.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| " Fifty-seven patients with postoperative breast cancer received MMF (mitomycin, methotrexate, futraful therapy with SNMC and 60 were given MMF alone." | 3.67 | [Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)]. ( Akimoto, M; Iwasaki, H; Kasai, M; Kimura, M; Matano, S; Nakajima, Y; Sawano, A, 1986) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 3.01 | Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021) |
| "Patients with recurrent or metastatic gastric cancer diagnosed by pathology were randomly divided into two groups to receive six cycles of either the TIROX regimen (21-day cycle) or the DCF regimen (21-day cycle)." | 2.79 | Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014) |
| "Patients with advanced or recurrent gastric cancer were randomly assigned to an experimental arm or a control arm." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| " Weekly paclitaxel combined with S-1 is a safe regimen and has a promising efficacy." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| " Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity." | 2.76 | [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011) |
| "Diarrhea was the most common type of nonhematologic toxicity: 3 patients had Grade 3 diarrhea." | 2.76 | A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. ( Hatate, K; Hayakawa, K; Ihara, A; Koizumi, W; Naito, M; Nakamura, T; Okayasu, I; Onosato, W; Ozawa, H; Sato, T; Watanabe, M; Yamashita, K, 2011) |
| "Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks." | 2.76 | Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011) |
| " Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle." | 2.75 | Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010) |
| " Based on the results of our previous phase I/II study in patients with gastric cancer, the dosage was established in consideration of safety for outpatient therapy." | 2.72 | [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen]. ( Asaka, M; Komatsu, Y; Kudo, M; Tateyama, M; Yuki, S, 2006) |
| "Paclitaxel was administered by intravenous drip infusion at a starting dose (level 1) of 50 mg/m2 on days 1, 8, and 15." | 2.72 | [A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer]. ( Doki, Y; Fujita, J; Fujiwara, Y; Kan, K; Miyata, H; Monden, M; Takiguchi, S; Tsukahara, K; Yasuda, T, 2006) |
| "He died of brain metastases." | 2.72 | [A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]. ( Asou, H; Ichinose, Y; Maruyama, R; Okamoto, T; Suemitsu, R; Wataya, H, 2006) |
| "Standard chemotherapy for advanced biliary tract cancer has not been established." | 2.72 | Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. ( Funakoshi, A; Furuse, J; Horikawa, Y; Ikeda, M; Ishii, H; Mizuno, N; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yamao, K, 2006) |
| " We assumed that the recommended dosage of TXT was 30 mg/m(2) and that of TS-1 was 60 mg/m(2) with radiotherapy of 60 Gy." | 2.72 | [A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1]. ( Higashida, M; Hirabayashi, Y; Hirai, T; Hiratsuka, J; Imajyo, Y; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K, 2006) |
| " Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps." | 2.71 | [Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004) |
| ") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers." | 2.71 | Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005) |
| "Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies." | 2.71 | A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Okusaka, T; Ueno, H, 2005) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Thirty-four patients with advanced gastric cancer were treated with combination chemotherapy employing Tegafur-Uracil (UFT), etoposide, Adriamycin, and Cisplatinum (CDDP) (UFT-EAP therapy)." | 2.67 | Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer. ( Chin, K; Hattori, T; Hayakawa, M; Maeda, H; Morise, K; Morooka, Y; Saito, H; Sugihara, M, 1994) |
| "Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial." | 2.46 | Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. ( Gao, XS; Li, XY; Liu, CX, 2010) |
| "Most cases of head and neck squamous cell carcinoma (HNSCC) are in the advanced stages, resulting in a poor prognosis." | 2.43 | [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma]. ( Horiuchi, C; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Toth, G; Tsukuda, M; Yoshida, T, 2006) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| " If it were possible to predict the development of bone marrow suppression before the white blood cell (WBC) count had actually decreased, treatment could be improved by strict dosage control and/or the prophylactic administration of hematopoietic drugs." | 1.38 | Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect. ( Matsumoto, C; Naito, Y; Ogawa, K; Omatsu, T; Tsuchiya, N; Yamamoto, M; Yoshikawa, T, 2012) |
| "To observe the local control rate, survival time and side effect of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma." | 1.37 | [Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma]. ( Li, WL; Liu, XH, 2011) |
| "Grade 3 leukocytopenia was observed in 1 patient (8." | 1.35 | Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. ( Dono, K; Kobayashi, S; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Takeda, Y; Umeshita, K; Wada, H, 2008) |
| "We report a case of recurrent gastric cancer with peritoneal dissemination and paraaortic lymph node metastases, successfully treated with weekly administration of paclitaxel." | 1.34 | [A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel]. ( Hirata, K; Ito, T; Sato, T; Takashima, T, 2007) |
| " The adverse effects observed were grade 3 leukopenia in 2 patients (11." | 1.33 | [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy]. ( Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R, 2006) |
| "As a measure to ensure safe use of TS-1 during the early marketing period, a drug use investigation was conducted on an all-case basis." | 1.33 | [Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--]. ( Ito, K, 2006) |
| "We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1." | 1.32 | [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. ( Mishima, K; Nakamura, H; Obara, S; Yamamoto, K; Yoshimura, Y, 2004) |
| "Although the effect of TS-1 alone on gastric cancer is significantly superior to that of any conventional cancer drugs, the results of this study suggest that the antitumor effect varies with the site of the target lesions and according to whether the lesion is a remnant or recurrence." | 1.32 | [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital]. ( Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H, 2003) |
| "The methods consisted of analysis of background factors, assessment of the administration and dosage of TS-1, and associations with adverse reactions." | 1.32 | [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients]. ( Hara, A; Iwamoto, S; Izumi, N; Satake, K; Takahashi, Y; Tokuhara, T, 2004) |
| "Five patients with inoperable advanced gastric cancer were treated with combination chemotherapy of TS-1 and cisplatin (CDDP)." | 1.31 | [TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy]. ( Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Nakaguchi, K; Nakamura, M; Sue, F; Tanaka, J; Yokouchi, H; Yoshihara, W, 2002) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (9.38) | 18.7374 |
| 1990's | 12 (12.50) | 18.2507 |
| 2000's | 49 (51.04) | 29.6817 |
| 2010's | 24 (25.00) | 24.3611 |
| 2020's | 2 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Hirahara, N | 1 |
| Matsubara, T | 1 |
| Kaji, S | 1 |
| Yamamoto, T | 1 |
| Hyakudomi, R | 1 |
| Takai, K | 1 |
| Ishitobi, K | 1 |
| Uchida, Y | 1 |
| Tajima, Y | 1 |
| Chen, Y | 1 |
| Gu, J | 1 |
| Yin, M | 1 |
| Wang, C | 1 |
| Chen, D | 1 |
| Yang, L | 1 |
| Chen, X | 1 |
| Lin, Z | 1 |
| Du, J | 1 |
| Cui, S | 1 |
| Ma, C | 1 |
| Luo, H | 1 |
| Wang, F | 1 |
| Fan, QX | 1 |
| Wang, HH | 1 |
| Han, DM | 1 |
| Song, NS | 1 |
| Lu, H | 1 |
| Niho, S | 1 |
| Hosomi, Y | 1 |
| Okamoto, H | 1 |
| Nihei, K | 1 |
| Tanaka, H | 2 |
| Hida, T | 1 |
| Umemura, S | 1 |
| Goto, K | 1 |
| Akimoto, T | 1 |
| Ohe, Y | 1 |
| Huang, D | 1 |
| Ba, Y | 2 |
| Xiong, J | 1 |
| Xu, N | 2 |
| Yan, Z | 2 |
| Zhuang, Z | 1 |
| Yu, Z | 3 |
| Wan, H | 1 |
| Zhang, Y | 2 |
| Deng, T | 2 |
| Zheng, R | 1 |
| Guo, Z | 1 |
| Hu, C | 1 |
| Wang, M | 1 |
| Yao, Y | 2 |
| Meng, J | 1 |
| Kaira, K | 2 |
| Tomizawa, Y | 1 |
| Yoshino, R | 1 |
| Yoshii, A | 1 |
| Matsuura, M | 1 |
| Iwasaki, Y | 2 |
| Koga, Y | 1 |
| Ono, A | 1 |
| Nishioka, M | 1 |
| Kamide, Y | 1 |
| Hisada, T | 2 |
| Ishizuka, T | 2 |
| Shirai, K | 1 |
| Ebara, T | 1 |
| Saitoh, J | 1 |
| Nakano, T | 1 |
| Sunaga, N | 2 |
| Dong, L | 1 |
| Li, J | 2 |
| Lou, XP | 1 |
| Miao, JH | 1 |
| Lu, P | 1 |
| Chang, ZW | 1 |
| Han, ZF | 1 |
| Nakamura, T | 3 |
| Yamashita, K | 3 |
| Sato, T | 5 |
| Ema, A | 1 |
| Naito, M | 2 |
| Watanabe, M | 4 |
| Arima, S | 1 |
| Shimizu, K | 2 |
| Okamoto, T | 2 |
| Toki, M | 1 |
| Suzuki, Y | 1 |
| Okano, N | 1 |
| Naruge, D | 1 |
| Kawai, K | 1 |
| Kobayashi, T | 2 |
| Kasuga, A | 1 |
| Kitamura, H | 1 |
| Takasu, A | 1 |
| Nagashima, F | 1 |
| Sugiyama, M | 1 |
| Furuse, J | 4 |
| Yanagitani, N | 1 |
| Aoki, H | 1 |
| Kawata, T | 1 |
| Utsugi, M | 1 |
| Shimizu, Y | 1 |
| Mori, M | 1 |
| Park, I | 1 |
| Lee, JL | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Sym, SJ | 1 |
| Lee, SS | 1 |
| Jang, G | 1 |
| Yoo, C | 1 |
| Bae, KS | 1 |
| Kang, YK | 1 |
| Oh, DY | 1 |
| Cha, Y | 1 |
| Choi, IS | 1 |
| Yoon, SY | 1 |
| Choi, IK | 1 |
| Kim, JH | 1 |
| Oh, SC | 1 |
| Kim, CD | 1 |
| Kim, JS | 2 |
| Bang, YJ | 1 |
| Kim, YH | 2 |
| Sasaki, T | 4 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Ito, Y | 1 |
| Kogure, H | 1 |
| Togawa, O | 1 |
| Toda, N | 1 |
| Yasuda, I | 1 |
| Hasebe, O | 1 |
| Maetani, I | 1 |
| Sasahira, N | 1 |
| Hirano, K | 1 |
| Tsujino, T | 1 |
| Tada, M | 1 |
| Omata, M | 1 |
| Koizumi, W | 4 |
| Akiya, T | 1 |
| Sato, A | 2 |
| Sakuyama, T | 2 |
| Sasaki, E | 1 |
| Tomidokoro, T | 1 |
| Hamada, T | 1 |
| Fujimori, M | 1 |
| Kikuchi, Y | 1 |
| Shimada, K | 1 |
| Mine, T | 1 |
| Yamaguchi, K | 2 |
| Kurihara, M | 3 |
| Yokoyama, T | 1 |
| Tokuhara, H | 1 |
| Egawa, T | 1 |
| Hashimoto, O | 1 |
| Seki, H | 1 |
| Koyanagi, K | 1 |
| Bessho, T | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 1 |
| Gao, F | 1 |
| Yanagihara, K | 1 |
| Yoshimura, K | 1 |
| Niimi, M | 1 |
| Yasuda, H | 1 |
| Nishimura, T | 1 |
| Ishiguro, H | 1 |
| Matsumoto, S | 1 |
| Kitano, T | 1 |
| Kanai, M | 1 |
| Misawa, A | 1 |
| Tada, H | 1 |
| Teramukai, S | 1 |
| Mio, T | 1 |
| Fukushima, M | 1 |
| Liu, CX | 1 |
| Li, XY | 1 |
| Gao, XS | 1 |
| Ozawa, H | 1 |
| Hatate, K | 1 |
| Onosato, W | 1 |
| Ihara, A | 1 |
| Hayakawa, K | 1 |
| Okayasu, I | 1 |
| Tsushima, T | 1 |
| Hironaka, S | 1 |
| Boku, N | 2 |
| Machida, N | 1 |
| Yamazaki, K | 2 |
| Yasui, H | 1 |
| Taku, K | 1 |
| Fukutomi, A | 1 |
| Onozawa, Y | 1 |
| Takagawa, R | 1 |
| Kunisaki, C | 2 |
| Makino, H | 1 |
| Nagano, Y | 1 |
| Fujii, S | 1 |
| Kimura, J | 1 |
| Kosaka, T | 1 |
| Ono, HA | 1 |
| Akiyama, H | 1 |
| Endo, I | 1 |
| Liu, XH | 1 |
| Li, WL | 1 |
| Komatsu, Y | 2 |
| Yuki, S | 2 |
| Sogabe, S | 1 |
| Fukushima, H | 1 |
| Iwanaga, I | 1 |
| Kudo, M | 2 |
| Tateyama, M | 2 |
| Meguro, T | 1 |
| Uebayashi, M | 1 |
| Saga, A | 1 |
| Sakata, Y | 2 |
| Asaka, M | 2 |
| Ueno, H | 3 |
| Okusaka, T | 3 |
| Yamao, K | 2 |
| Funakoshi, A | 2 |
| Ohkawa, S | 1 |
| Yokosuka, O | 1 |
| Tanaka, K | 1 |
| Moriyasu, F | 1 |
| Nakamori, S | 2 |
| Nakayama, N | 1 |
| Tanabe, S | 1 |
| Higuchi, K | 1 |
| Nishimura, K | 1 |
| Takagi, S | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Ishido, K | 1 |
| Nakatani, K | 1 |
| Naruke, A | 1 |
| Katada, C | 1 |
| Zhu, QC | 1 |
| Jin, ZM | 1 |
| Ogawa, K | 2 |
| Omatsu, T | 1 |
| Matsumoto, C | 1 |
| Tsuchiya, N | 1 |
| Yamamoto, M | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
| Huang, DZ | 1 |
| Xiong, JP | 1 |
| Zhuang, ZX | 1 |
| Wan, HP | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 1 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Yu, ZH | 1 |
| Meng, JC | 1 |
| Nakamura, M | 2 |
| Maruyama, K | 1 |
| Furukawa, J | 1 |
| Maruyama, N | 1 |
| Tanaka, J | 1 |
| Katsumoto, Y | 1 |
| Yokouchi, H | 1 |
| Nakaguchi, K | 2 |
| Sue, F | 1 |
| Yoshihara, W | 1 |
| Nishino, H | 1 |
| Shinozaki, T | 1 |
| Ishikawa, K | 1 |
| Ichimura, K | 1 |
| Abe, S | 1 |
| Kojima, M | 1 |
| Tamura, H | 1 |
| Kurihara, H | 1 |
| Kitago, M | 1 |
| Ogihara, T | 1 |
| Chen, JS | 1 |
| Yang, TS | 1 |
| Lin, YC | 1 |
| Jan, YY | 1 |
| Arai, K | 1 |
| Kimura, Y | 2 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Honma, S | 1 |
| Takahashi, T | 2 |
| Tujie, M | 1 |
| Takahashi, Y | 2 |
| Maruhashi, S | 1 |
| Miyamoto, A | 2 |
| Nagano, H | 2 |
| Dono, K | 2 |
| Umeshita, K | 2 |
| Sakon, M | 1 |
| Monden, M | 4 |
| Yamamura, Y | 1 |
| Kodera, Y | 1 |
| Tanemura, H | 1 |
| Oshita, H | 1 |
| Miyashita, K | 1 |
| Fujimura, T | 1 |
| Aotake, T | 1 |
| Yamamoto, H | 1 |
| Tanaka, F | 1 |
| Fujii, H | 1 |
| Hirose, Y | 1 |
| Matsushita, T | 1 |
| Morita, S | 1 |
| Ohashi, Y | 2 |
| Hirakawa, K | 1 |
| Nakata, B | 1 |
| Saji, S | 1 |
| Sakamoto, J | 1 |
| Saeki, T | 1 |
| Takashima, S | 2 |
| Sano, M | 2 |
| Horikoshi, N | 4 |
| Miura, S | 1 |
| Shimizu, S | 1 |
| Morimoto, K | 2 |
| Kimura, M | 3 |
| Taguchi, T | 4 |
| Hara, A | 1 |
| Tokuhara, T | 1 |
| Izumi, N | 1 |
| Iwamoto, S | 1 |
| Satake, K | 1 |
| Makari, Y | 1 |
| Fujiwara, Y | 2 |
| Yasuda, T | 2 |
| Takiguchi, S | 2 |
| Yano, M | 1 |
| Yamamoto, K | 1 |
| Obara, S | 1 |
| Mishima, K | 1 |
| Nakamura, H | 1 |
| Yoshimura, Y | 1 |
| Watanabe, O | 1 |
| Shimizu, T | 1 |
| Imamura, H | 1 |
| Kinoshita, J | 1 |
| Okabe, T | 1 |
| Haga, S | 1 |
| Yokoyama, M | 1 |
| Ogawa, M | 3 |
| Takao, Y | 1 |
| Sato, K | 1 |
| Kawahara, H | 1 |
| Anazawa, S | 1 |
| Yamazaki, Y | 1 |
| Hirai, K | 1 |
| Woo, IS | 1 |
| Moon, DH | 1 |
| Shim, BY | 1 |
| Lee, MA | 1 |
| Byun, JH | 1 |
| Kim, KW | 1 |
| Kang, JH | 1 |
| Choi, MG | 1 |
| Chung, IS | 1 |
| Hong, YS | 1 |
| Park, SY | 1 |
| Lee, KS | 1 |
| Nio, Y | 1 |
| Hashimoto, K | 1 |
| Yano, S | 1 |
| Itakura, M | 1 |
| Koike, M | 1 |
| Endo, S | 1 |
| Tsuji, M | 1 |
| Higami, T | 1 |
| Maruyama, R | 2 |
| Ikeda, M | 2 |
| Morizane, C | 2 |
| Ishii, H | 2 |
| Sadahiro, S | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 1 |
| Nukaya, H | 1 |
| Hirashima, N | 1 |
| Tanaka, Y | 1 |
| Endo, M | 1 |
| Matsunaga, S | 1 |
| Hasegawa, I | 1 |
| Kato, A | 1 |
| Sakakibara, K | 1 |
| Sakamoto, T | 1 |
| Kondo, H | 1 |
| Fujita, J | 1 |
| Kan, K | 1 |
| Tsukahara, K | 1 |
| Miyata, H | 1 |
| Doki, Y | 1 |
| Ito, K | 1 |
| Takahashi, I | 2 |
| Emi, Y | 1 |
| Kakeji, Y | 2 |
| Tokunaga, E | 1 |
| Ushiro, S | 1 |
| Oki, E | 2 |
| Baba, H | 1 |
| Maehara, Y | 2 |
| Wataya, H | 1 |
| Asou, H | 1 |
| Suemitsu, R | 1 |
| Ichinose, Y | 2 |
| Akasu, T | 1 |
| Moriya, Y | 1 |
| Yoshida, S | 1 |
| Shirao, K | 2 |
| Kodaira, S | 1 |
| Itoi, A | 1 |
| Takashima, M | 1 |
| Ishimasa, H | 1 |
| Murata, H | 1 |
| Tomoda, K | 1 |
| Ishida, H | 1 |
| Akita, H | 1 |
| Watanabe, Y | 1 |
| Kabuto, T | 1 |
| Nagase, M | 1 |
| Nakachi, K | 1 |
| Horikawa, Y | 1 |
| Mizuno, N | 1 |
| Shitara, K | 1 |
| Kudou, T | 1 |
| Munakata, M | 1 |
| Ohtsu, A | 1 |
| Yoshida, K | 1 |
| Wada, Y | 1 |
| Tanabe, K | 1 |
| Ukon, K | 1 |
| Hihara, J | 1 |
| Egashira, A | 1 |
| Morita, M | 1 |
| Hokita, S | 1 |
| Aikou, T | 1 |
| Ishigami, S | 1 |
| Miyazono, F | 1 |
| Nakajo, A | 1 |
| Uenosono, Y | 1 |
| Hamanoue, M | 1 |
| Aridome, K | 1 |
| Natsugoe, S | 1 |
| Eguchi, T | 1 |
| Goto, A | 1 |
| Tsunoda, A | 1 |
| Nakao, K | 2 |
| Kamiyama, G | 1 |
| Narita, K | 1 |
| Suzuki, N | 1 |
| Oonaka, T | 1 |
| Kusano, M | 1 |
| Tsuji, H | 1 |
| Nagata, M | 1 |
| Inoue, T | 1 |
| Minami, T | 1 |
| Iwai, H | 1 |
| Ohnishi, S | 1 |
| Yukawa, H | 1 |
| Ogura, M | 1 |
| Yamashita, T | 1 |
| Nagata, K | 1 |
| Tsukuda, M | 2 |
| Ishitoya, J | 1 |
| Mikami, Y | 1 |
| Matsuda, H | 1 |
| Katori, H | 1 |
| Horiuchi, C | 1 |
| Yoshida, T | 1 |
| Toth, G | 1 |
| Tahara, M | 1 |
| Nakazawa, M | 1 |
| Hatori, S | 1 |
| Ono, H | 1 |
| Otsuka, Y | 1 |
| Yamada, R | 1 |
| Ohshima, T | 1 |
| Rino, Y | 1 |
| Imada, T | 1 |
| Inaji, H | 1 |
| Sakai, K | 1 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 1 |
| Senoo, T | 1 |
| Terasawa, T | 1 |
| Mori, T | 1 |
| Koyama, H | 1 |
| Oshima, A | 1 |
| Matsumoto, H | 1 |
| Hirai, T | 1 |
| Hirabayashi, Y | 1 |
| Murakami, H | 1 |
| Higashida, M | 1 |
| Kawabe, Y | 1 |
| Urakami, A | 1 |
| Hiratsuka, J | 1 |
| Imajyo, Y | 1 |
| Tsunoda, T | 1 |
| Maruoka, Y | 1 |
| Ando, T | 2 |
| Ogiuchi, Y | 1 |
| Ogiuchi, H | 1 |
| Takashima, T | 1 |
| Ito, T | 1 |
| Hirata, K | 1 |
| Marubashi, S | 1 |
| Takeda, Y | 1 |
| Kobayashi, S | 1 |
| Wada, H | 1 |
| Noda, T | 1 |
| Salvati, F | 1 |
| Cruciani, AR | 1 |
| De Marinis, A | 1 |
| Nunziati, F | 1 |
| Portalone, L | 1 |
| Ansfield, FJ | 1 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Inoue, K | 2 |
| Inagaki, J | 1 |
| Ikeda, K | 1 |
| Nakada, H | 1 |
| Usui, N | 1 |
| Adachi, K | 1 |
| Tada, A | 1 |
| Yamazaki, H | 1 |
| Hasegawa, K | 1 |
| Takahashi, M | 1 |
| Akazawa, S | 1 |
| Fukuyama, Y | 1 |
| Hayakawa, M | 3 |
| Sasai, T | 1 |
| Kimura, K | 1 |
| Sanchiz, F | 1 |
| Milla, A | 1 |
| Shinoda, M | 1 |
| Morise, K | 3 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Ina, K | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Oka, Y | 1 |
| Chin, K | 1 |
| Sugihara, M | 1 |
| Morooka, Y | 1 |
| Maeda, H | 1 |
| Hattori, T | 1 |
| Saito, H | 1 |
| Feliu, J | 1 |
| Gonzalez-Baron, M | 1 |
| Espinosa, E | 1 |
| de Castro, J | 1 |
| Ordonez, A | 1 |
| Zamora, P | 1 |
| Gomez-Navarro, J | 1 |
| Espinosa, J | 1 |
| Vilches, Y | 1 |
| de la Gandara, I | 1 |
| Ono, T | 1 |
| Komatsu, M | 1 |
| Hoshino, T | 1 |
| Ishii, T | 1 |
| Fujii, K | 1 |
| Ohshima, S | 1 |
| Mikami, K | 1 |
| Masamune, O | 1 |
| Fukuda, T | 1 |
| Abad, A | 1 |
| Navarro, M | 1 |
| Sastre, J | 1 |
| Marcuello, E | 1 |
| Aranda, E | 1 |
| Gallén, M | 1 |
| Fernandez-Martos, C | 1 |
| Martín, C | 1 |
| Diaz-Rubio, E | 1 |
| Yano, T | 1 |
| Kudoh, S | 1 |
| Yoshimori, K | 1 |
| Morikawa, T | 1 |
| Kuba, M | 1 |
| Niitani, H | 1 |
| Shin, SW | 1 |
| Kim, BS | 1 |
| Park, YT | 1 |
| Kim, JG | 1 |
| Toge, T | 1 |
| Aoyama, H | 1 |
| Ota, J | 1 |
| Noguchi, S | 1 |
| Inuyama, Y | 1 |
| Kida, A | 1 |
| Kohno, N | 1 |
| Satake, B | 1 |
| Lichinitser, MR | 1 |
| Perevodchikova, NI | 1 |
| Garin, AM | 1 |
| Asserkritova, IV | 1 |
| Vaarik, GKh | 1 |
| Diggs, CH | 1 |
| Wiernik, PH | 1 |
| Smyth, AC | 1 |
| Sakai, T | 1 |
| Thin, K | 1 |
| Kokubu, K | 1 |
| Akatsuka, Y | 1 |
| Sato, Y | 1 |
| Tahara, H | 1 |
| Kuwahara, Y | 1 |
| Ninomiya, Y | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 1 |
| Miwa, M | 1 |
| Ishitsuka, H | 1 |
| Akimoto, M | 1 |
| Sawano, A | 1 |
| Iwasaki, H | 1 |
| Nakajima, Y | 1 |
| Matano, S | 1 |
| Kasai, M | 1 |
| Shinagawa, K | 1 |
| Mukaiyama, T | 1 |
| Fukutani, H | 1 |
| Tabata, M | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of UFT Compared With Surgery Alone in Patients With Dukes C Colorectal Cancer (NSAS-CC)[NCT00152230] | Phase 3 | 900 participants (Anticipated) | Interventional | 1996-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for tegafur and Leukocytopenia
| Article | Year |
|---|---|
Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell | 2010 |
[An investigation of TS-1 single-agent therapy administered as first-line therapy for unresectable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Inj | 2005 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer].
Topics: Animals; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic | 2006 |
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2006 |
[Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
Topics: Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Ad | 2006 |
59 trials available for tegafur and Leukocytopenia
| Article | Year |
|---|---|
Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2021 |
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; | 2017 |
Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2019 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Dr | 2013 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co | 2017 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat | 2010 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatig | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2010 |
Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Fatigue; Fema | 2010 |
Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease | 2010 |
A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ad | 2011 |
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Admi | 2012 |
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo | 2011 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neo | 2003 |
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Admini | 2003 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; D | 2004 |
[A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administratio | 2004 |
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
[Clinical usefulness of UFT and cyclophosphamide as salvage chemotherapy for patients with metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Prot | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2005 |
A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Drug Adm | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
[A phase I study of combination chemotherapy using TS-1 and weekly paclitaxel for advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug | 2006 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Dr | 2006 |
Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chemot | 2006 |
[Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia, Megaloblastic; Antimetabolites, Antineoplasti | 2006 |
Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio | 2006 |
[Combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dose-Re | 2006 |
[Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2006 |
[Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal | 2006 |
[Clinical phase I trial of concurrent chemo-radiotherapy with S-1 for T2NO glottic carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deglutit | 2006 |
[Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cispl | 2006 |
[Preoperative chemotherapy with S-1 and low-dose cisplatin for oral squamous cell carcinoma].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
[A phase I/II study of docetaxel/TS-1 with radiation for esophageal cancer patients--step 1].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel | 2006 |
[A randomized trial of adriamycin, cyclophosphamide, ftorafur (ACF) and adriamycin, cyclophosphamide, ftorafur, methotrexate (ACFM) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1984 |
[Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer. UFTP Study Group].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug A | 1995 |
Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Humans; L | 1994 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; | 1994 |
Cisplatin and UFT modulated with leucovorin for the treatment of Advanced non-small-cell lung cancer.
Topics: Abdominal Pain; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1996 |
A preliminary report of a phase II trial. UFT plus oral folinic acid as therapy for metastatic colorectal cancer in older patients. Spanish Group for the Treatment of Gastrointestinal Tumors (TTd Group).
Topics: Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl | 1997 |
UFT plus cisplatin in advanced non-small-cell lung cancer: interim analysis of 67 patients.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cispla | 1997 |
UFT plus cisplatin for advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrh | 1997 |
A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Diarrhea; Drug Co | 1997 |
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati | 1998 |
[Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Ce | 1998 |
28 other studies available for tegafur and Leukocytopenia
| Article | Year |
|---|---|
[The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dise | 2009 |
Second-line docetaxel plus cisplatin for advanced gastric cancer showing resistance to S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2011 |
[Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; E | 2011 |
Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood Cell Count; Bone Marrow; Drugs, Chinese Herbal; Fe | 2012 |
[TS-1/CDDP therapy for advanced gastric cancer as neoadjuvant chemotherapy].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedul | 2002 |
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Co | 2002 |
[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration | 2003 |
[A case of postoperative chestwall recurrence of gastric cancer responding to a combination of radiation, hyperthermia and oral administration of TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Sch | 2004 |
[Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Topics: Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug Administration Schedul | 2004 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedu | 2004 |
[An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administrat | 2004 |
[Home chemotherapy by concomitant UFT + Leucovorin (po.) in postoperative colorectal cancer patients assessed with Dukes D and curability C colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administration | 2004 |
[Example of safety measures for antineoplastic agents immediately after market launch--a case of TS-1 capsule all example use result investigation that executes safety monitoring--].
Topics: Antimetabolites, Antineoplastic; Capsules; Drug Administration Schedule; Drug Combinations; Drug Mon | 2006 |
[Complete response to CPT-11 and UFT/LV combination therapy in a case with simultaneous multiple lung metastases from colon cancer].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neop | 2006 |
[Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Dr | 2006 |
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administrat | 2006 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[A case of S-1-resistant recurrent gastric cancer successfully treated with weekly administration of paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Combin | 2007 |
Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2008 |
Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Br | 1984 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration | 1996 |
[Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer].
Topics: Adult; Altretamine; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leuko | 1978 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
[Combination chemotherapy with UFT, etoposide, CDDP, adriamycin (FEPA) in advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1989 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
[Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Glycyrrhetini | 1986 |
[Phase II study of combination chemotherapy with epirubicin, cyclophosphamide and ftorafur in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1988 |